FDA Needs To Track Actions Built On Supplement AERs – GAO Report
This article was originally published in The Pink Sheet Daily
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.
You may also be interested in...
At its start in 2006 and for a few subsequent sessions, the caucus wasn't well known and receiving the Administration Committee's acknowledgement that it was an authorized congressional membership group wasn't routine. Returning members had to renew their membership with each session, too.
Regular under-reporting of serious adverse event reports has spurred FDA to have its good manufacturing practice inspectors review dietary supplement firms’ AERs and reporting practices, FDA’s Fabricant says. Key compliance issues can tip off the agency that a company may be falling short on reporting.
GMP violations lead to prison time; Syntec supplements seized; FDA warns NanoLiposomal Nutritionals; and more Enforcement In Brief.